Results 71 to 80 of about 125,690 (294)

Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Dedicated hypertrophic cardiomyopathy (HCM) center cohorts have reported reductions in HCM‐related deaths, likely due to the introduction of contemporary treatments.
Ahmed Sayed, Barry J. Maron, Ethan J. Rowin, Martin S. Maron   +3 more
doaj   +1 more source

Determinants of cardiopulmonary exercise test responses in hypertrophic cardiomyopathy [PDF]

, 2023
Giulia Foccardi, Kiril Chernis, Giulia Quinto, Veronica Baioccato, Marco Vecchiato, Sara Ortolan, Francesca Battista, Daniel Neunhäeuserer, Andrea Ermolao, Andrea Gasperetti   +9 more
openalex   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Explainable artificial intelligence identifies and localizes left ventricular scar in hypertrophic cardiomyopathy using 12-Lead electrocardiogram

Scientific Reports
Left ventricular (LV) scar is a major risk factor for sudden death and heart failure in hypertrophic cardiomyopathy (HCM). LV scar evolves over time and needs longitudinal assessment. Currently, LV scar detection relies on late gadolinium enhancement MRI,
Kasra Nezamabadi, Sanjay Sivalokanathan, Jiwon Lee, Talha Tanriverdi, Meiling Chen, Daiyin Lu, Jadyn Abraham, Neda Sardaripour, Pengyuan Li, Parvin Mousavi, M. Roselle Abraham   +10 more
doaj   +1 more source

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]

, 2020
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark, Paik, David T, Wu, Joseph C   +2 more
core  

The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy [PDF]

, 2008
Background: Hypertrophic (HCM) and dilated (DCM) cardiomyopathies results from sarcomeric protein mutations, including cardiac troponin T (cTnT, TNNT2).
Ahmad, F, Banerjee, SK, Conner, DA, Huang, XN, Janczewski, AM, Keller, BB, Lage, ML, Mathier, MA, Moskowitz, IP, Perez-Atayde, AR, Rager, J, Saba, S, Seidman, CE, Seidman, JG, Shroff, SG, Smith, SH, Tinney, JP, Tobita, K   +17 more
core   +4 more sources

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

Automatic Segmentation and Disease Classification Using Cardiac Cine MR Images

, 2017
Segmentation of the heart in cardiac cine MR is clinically used to quantify cardiac function. We propose a fully automatic method for segmentation and disease classification using cardiac cine MR images.
Isgum, Ivana, Leiner, Tim, Viergever, Max A., Wolterink, Jelmer M.   +3 more
core   +2 more sources